Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

{
  "signal_id": "58caeca2-4d48-2097-7540-caf134b6df91",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-08-04T10:34:21+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/08/04/merck-mrk-earnings-q2-2026.html",
    "title": "Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges",
    "excerpt": "In this article Merck on Tuesday beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth. But the pharmaceutical giant cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals. Merck now anticipates its 2026 revenue will come in between $66.3 billion and $67.3 billion, up from a previous guidance of $65.8 billion and $67 billion. The company also expects adjusted earnings to be between $2.66 and $2.76 per share, which now includes a one-time charge of $5.7 billion, or $2.31 per share, related to the Terns deal. It also includes a $9 billion, or $3.62 per share, charge related to Merck's acquisition of Cidara Therapeutics in January. That adjusted profit outlook is down from a previous range of $5.04 to $5.16 per share. Merck has been on a buying spree as it races to offset generic competition for a few drugs, including Type 2 diabetes medications Januvia and Janumet later this year, and blockbuster immunotherapy Keytruda in 2028. The company is also betting on a newer drugs to replenish potential losses in revenue, including the first PCSK9 pill designed to lower bad cholesterol , which was approved in July. Here's what Merck reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: The company posted a net loss of...",
    "summary": "Merck acquired Cidara Therapeutics in January, resulting in a $9 billion charge.",
    "planning": false,
    "image_url": "https://image.cnbcfm.com/api/v1/image/107405221-1713892565815-gettyimages-1988355170-scooter262243_5r57gm4x.jpeg?v=1750955954&w=1920&h=1080",
    "confidence": 0.9,
    "published_at": "2026-08-04T10:34:21Z",
    "article_sentence": "It also includes a $9 billion, or $3.62 per share, charge related to Merck's acquisition of Cidara Therapeutics in January.",
    "amount_normalized": 9000000000,
    "related_company_name": "Cidara Therapeutics",
    "related_company_domain": "cidara.com"
  }
}

curl https://signals.autobound.ai/v1/signals/58caeca2-4d48-2097-7540-caf134b6df91 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"merck.com","limit":20}'